Neuberger Berman Group
KPTI icon

Neuberger Berman Group’s Karyopharm Therapeutics KPTI Stock Holding History

Neuberger Berman Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,530
Closed -$19.9K – 1963
2024
Q2 		$19.9K Buy
+1,530
New +$25.3K ﹤0.01% 1873
2024
Q1 		– Sell
-1,776
Closed -$23K – 1880
2023
Q4 		$23K Buy
1,776
+1,027
+137% +$13.8K ﹤0.01% 1847
2023
Q3 		$15.1K Buy
+749
New +$16.8K ﹤0.01% 1782

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Neuberger Berman Group's KPTI Position: Q3 2024 in Review

Neuberger Berman Group sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 1,530 shares — an estimated $19.9K sold.

Neuberger Berman Group first reported a position in KPTI in Q3 2023 and held it in 3 quarters. The position peaked at $23K in Q4 2023. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Neuberger Berman Group reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 1,530 Karyopharm Therapeutics shares in Q3 2024, an estimated $19.9K.
  • Neuberger Berman Group first reported a position in Karyopharm Therapeutics in Q3 2023 and held it in 3 quarters.
  • Neuberger Berman Group's Karyopharm Therapeutics position peaked at $23K in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Neuberger Berman Group's 13F filing for Q3 2024, filed 14 Nov 2024.